 This is a placebo-controlled, multi-centre, 2-arm randomised phase II trial of Paclitaxel AZD5363 versus Paclitaxel placebo in patients with triple-negative ER-negative, PR-negativeunknown, HER2-negative advanced or metastatic breast cancer. 